Grail: High-Risk Bet on the Revolution of Cancer Diagnostics

The company Grail is a biotechnology and healthcare firm whose main business is the early detection of cancer. Grail is a leader in the development of the Galleri test, an innovative blood test for the early detection of over 50 types of cancer that has the potential to revolutionize cancer screening. Cooperations, such as the recent one with the Samsung Group to expand into the Asian market, underline the global potential and can accelerate growth outside of the home market, the USA. The stock of Grail (NASDAQ: GRAL) represents a highly...